Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2020

View Archived Issues

Unexpected mechanism, combination possibilities for CDK4/6 inhibitors

In SIV infection, gut integrity is retained, not repaired

Stromal FOXC1 and tumoral ERK1-2, p38 as prognostic biomarkers in DLBCL

A panel of markers found to distinguish thymomas from thymic carcinomas

Scale-up synthesis and characterization of a TRPV1 agonist with strong topical analgesic activity

Transplantation of NSCs overexpressing Wnt4 shows preclinical utility for spinal cord injuries

New STAT3 inhibitor inhibits tumor growth and metastasis in preclinical models of colorectal cancer

Results from first-in-human study of [11C]SMW-139 as an in vivo neuroinflammation tracer in MS

Update on clinical development of opaganib

Safety and PK data presented for GS-9722

Phase I results for rectally administered microbicide gel formulated with IQP-0528

Aberrant DNA methylation predicts survival in acral melanoma

U.S. researchers present biodegradable implant for antiretroviral contraceptive delivery

Phase III GY004 study does not meet primary endpoint

Newave Pharmaceutical patents Bcl-2 inhibitors

Phase II study of MK-1454 and pembrolizumab in HNSCC initiated

Corvus Pharmaceuticals discloses adenosine receptor modulators

CANBERRA trial to evaluate RG-7774 in diabetic retinopathy

GlaxoSmithKline and ViiV Healthcare present compounds for HIV infection

Phase I/II trial of NEXI-001 underway in AML/MDS relapsing after hematopoietic cell transplant

Sunshine Lake Pharma discovers HBsAg inhibitors for HBV infections

New CD73 inhibitors presented by Eternity Bioscience

With Uhambo's and research lessons, once more unto the breach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...